Skip to main content
. Author manuscript; available in PMC: 2014 Feb 27.
Published in final edited form as: Lancet Oncol. 2012 Sep 4;13(10):1011–1019. doi: 10.1016/S1470-2045(12)70344-3

Figure 1. Waterfall plot of best percent change in target lesions from baseline for 133* patients on the basis of investigator assessment.

Figure 1

*Excludes patients with early death before re-imaging, non-measurable non-target disease, or indeterminate responses: five patients with a best overall response of indeterminate either had available on-study scans that could not be assessed or discontinued the study before to obtaining adequate scans to assess response; three patients died within 42 days from first dose; and two patients had non-target lesions only.